Oppenheimer & Co. Inc. Raises Holdings in Cara Therapeutics, Inc. (NASDAQ:CARA)

Oppenheimer & Co. Inc. lifted its holdings in shares of Cara Therapeutics, Inc. (NASDAQ:CARAGet Rating) by 37.3% during the second quarter, according to its most recent disclosure with the SEC. The fund owned 17,130 shares of the biopharmaceutical company’s stock after acquiring an additional 4,650 shares during the period. Oppenheimer & Co. Inc.’s holdings in Cara Therapeutics were worth $156,000 at the end of the most recent quarter.

A number of other large investors have also modified their holdings of the business. Los Angeles Capital Management LLC purchased a new stake in shares of Cara Therapeutics during the second quarter worth about $624,000. IQ EQ FUND MANAGEMENT IRELAND Ltd grew its stake in shares of Cara Therapeutics by 5.0% during the second quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 132,879 shares of the biopharmaceutical company’s stock worth $1,213,000 after acquiring an additional 6,372 shares during the last quarter. Pinnacle Associates Ltd. grew its stake in shares of Cara Therapeutics by 0.4% during the second quarter. Pinnacle Associates Ltd. now owns 742,708 shares of the biopharmaceutical company’s stock worth $6,781,000 after acquiring an additional 2,602 shares during the last quarter. New York State Teachers Retirement System grew its stake in shares of Cara Therapeutics by 66.0% during the second quarter. New York State Teachers Retirement System now owns 78,444 shares of the biopharmaceutical company’s stock worth $716,000 after acquiring an additional 31,200 shares during the last quarter. Finally, Victory Capital Management Inc. purchased a new stake in shares of Cara Therapeutics during the second quarter worth about $1,221,000. Hedge funds and other institutional investors own 65.00% of the company’s stock.

Cara Therapeutics Trading Up 0.2 %

Shares of NASDAQ:CARA opened at $10.98 on Friday. Cara Therapeutics, Inc. has a 12-month low of $7.40 and a 12-month high of $14.72. The company has a market capitalization of $589.96 million, a PE ratio of -6.61 and a beta of 0.93. The business has a 50 day moving average of $9.79 and a two-hundred day moving average of $9.56.

Insider Buying and Selling at Cara Therapeutics

In other Cara Therapeutics news, Director Martin Vogelbaum sold 10,800 shares of the business’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $10.28, for a total value of $111,024.00. Following the completion of the transaction, the director now directly owns 44,988 shares of the company’s stock, valued at $462,476.64. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In other news, CEO Christopher Posner sold 14,470 shares of the company’s stock in a transaction that occurred on Wednesday, November 16th. The stock was sold at an average price of $11.13, for a total transaction of $161,051.10. Following the completion of the transaction, the chief executive officer now directly owns 186,561 shares of the company’s stock, valued at approximately $2,076,423.93. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Martin Vogelbaum sold 10,800 shares of the company’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $10.28, for a total value of $111,024.00. Following the transaction, the director now directly owns 44,988 shares of the company’s stock, valued at $462,476.64. The disclosure for this sale can be found here. 3.20% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities research analysts recently commented on the company. Piper Sandler decreased their target price on Cara Therapeutics to $25.00 in a report on Tuesday, November 15th. StockNews.com assumed coverage on Cara Therapeutics in a report on Wednesday, October 12th. They set a “hold” rating for the company. One research analyst has rated the stock with a hold rating and three have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $26.60.

Cara Therapeutics Profile

(Get Rating)

Cara Therapeutics, Inc, an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells.

Featured Stories

Institutional Ownership by Quarter for Cara Therapeutics (NASDAQ:CARA)

Receive News & Ratings for Cara Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cara Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.